Investment Agreement completed by CollPlant

CollPlant, a regenerative medicine company which uses its proprietary plant-based rhCollagen technology for tissue repair products, just announced that it has completed the third and final closing of its investment agreement with Alpha Capital Anstalt, and issued the company a pre-paid warrant to purchase up to 9,921,482 ordinary shares, represented by 198,430 American Depositary Shares (ADSs), as well as a warrant to purchase up to 49,607,407 ordinary shares represented by 992,149 ADSs. The exercise price NIS 36.14 per ADS ($10.07 per ADS), with gross proceeds equaling $1 million, and both warrants were offered up in a private placement.

CollPlant rhCollagen-based medical products.

“With this last phase of investment, we are concluding a series of rounds of financing over the past seven months in CollPlant totaling approximately $8 million. These rounds were participated in by Alpha and our largest shareholders,”

-Yehiel Tal, CollPlant’s CFO-

and follows,

 “The main use of proceeds of these funds were for the establishment of a new cGMP production facility in Israel, the investment in the development projects that we have with 3D bio-printing of tissues and organs, R&D, sales and marketing and working capital and general corporate purposes.”